Bristol-Myers Squibb India Private Limited

Bristol-Myers Squibb India Private Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN U24230MH2004FTC147232 Incorporated 30 June 2004 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Foreign Private Limited Company pharma Fortune MNC 500 · #395
Revenue · FY 2025
₹881.76 Cr
▲ 40% YoY
Net profit · FY 2025
₹81.69 Cr
Net margin 9.3%
EBITDA · FY 2025
₹128.15 Cr
EBITDA margin 14.5%
Authorised capital
₹350 Cr
Registered with MCA
Paid-up capital
₹346.91 Cr
Issued & subscribed
Company age
22 yrs
Est. 2004
Directors on board
4
As per MCA filings
Active GSTINs
3
of 4 registered

About Bristol-Myers Squibb India Private Limited

Data last updated:

Bristol-Myers Squibb India Private Limited is a foreign private limited company based in Mumbai, Maharashtra, India, a subsidiary of Bms Pharmaceuticals International Holdings Netherlands B.V.. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 30 June 2004 and has been in existence for over 22 years.

Bristol-Myers Squibb India is ranked #395 on the Fortune MNC 500 India (2026).

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24230MH2004FTC147232. Its GSTIN is 27AACCB4313Q1ZI (Maharashtra). The company holds 4 GST registrations, of which 3 are active.

The company has an authorised share capital of ₹350 Cr and a paid-up capital of ₹346.91 Cr. It is led by directors including Sanjay Sharma and Raghavendra Agarwal.

Its last annual general meeting (AGM) was held on 22 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at One International Center 6th Floor Tower 1 Senapati Bapat Marg Elphinstone (W), Mumbai, Maharashtra, India – 400013.

As per the financials filed for FY 2025, the company reported a revenue of ₹881.76 Cr, a growth of 40% compared to the previous year. For the same year it recorded a net profit of ₹81.69 Cr (net margin 9.3%) and EBITDA of ₹128.15 Cr (EBITDA margin 14.5%). Revenue has grown at a compounded annual rate (CAGR) of 41% over three years and 21% over five years.

The company is associated with 1 brand: Bristol-Myers Squibb. Court records list 8 cases involving the company, including 2 filed by the company and 6 filed against it; 4 cases are pending. The company has 6 deals on record (5 funding rounds, 1 rights issue), with disclosed funding of ₹294.86 Cr; the latest was in October 2015. Its 4 peer companies in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading) are compared by revenue, 3 larger and 1 smaller; the largest is Merck Specialities Private Limited with revenue of ₹1,027.41 Cr. The company has 8 MSME Form 1 returns on record between 2018 and 2024, listing 38 overdue payments to 12 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website bms.com.

Company details

CIN U24230MH2004FTC147232
Registration Number 147232
Incorporation Date 30 June 2004
ROC Mumbai
Listing Status Unlisted
Company Status Active
Parent Company Bms Pharmaceuticals International Holdings Netherlands B.V.
Compliance Status Active Compliant

CIN history

Bristol-Myers Squibb India has one previous CIN (Corporate Identification Number): U24230MH2004PTC147232. The current CIN is U24230MH2004FTC147232, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
U24230MH2004FTC147232Current
U24230MH2004PTC147232Previous

Recognitions & Rankings of Bristol-Myers Squibb India

Fortune MNC 500 India 2026 edition
Rank#395
Total income
₹755 Cr
Profit
₹73 Cr
Last year #378

Contact details

Bristol-Myers Squibb India Private Limited's registered office is in Mumbai, Maharashtra. Its website is bms.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
  • Social Media
  • Registered Address
    One International Center 6th Floor Tower 1 Senapati Bapat Marg Elphinstone (W), Mumbai, Maharashtra, India – 400013
  • Industry
    Pharma, Pharmaceutical Retailers & Distributors, Pharma Contract R&D

To see the full contact details of Bristol-Myers Squibb India Private Limited, buy the company report.

Comprehensive company report
Bristol-Myers Squibb India Private Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Bristol-Myers Squibb India operates one associated brand: Bristol-Myers Squibb. Each brand links to its own profile.

BrandDescriptionWebsite
Manufacturer of drugs for oncology, HIV/AIDS, cardiovascular disease, rheumatoid arthritis, and hepatitisbms.com

Business activity

The main business activity of Bristol-Myers Squibb India is trade. In detail, this covers wholesale trading.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
GTradeG1Wholesale Trading

To see the full business activity and turnover split of Bristol-Myers Squibb India Private Limited, buy the company report.

Financials of Bristol-Myers Squibb India Private Limited

FY 2025 filings available

Bristol-Myers Squibb India Private Limited reported revenue of ₹881.76 Cr (up 40% YoY) for FY 2025.

Revenue · FY 2025
₹881.76 Cr ▲ 40%
Net profit · FY 2025
₹81.69 Cr margin 9.3%
EBITDA · FY 2025
₹128.15 Cr margin 14.5%

Compounded Annual Growth Rate (CAGR)

Revenue CAGR growth
1 year
▲ 40%
3 years · compounded
▲ 41%
5 years · compounded
▲ 21%
EBITDA CAGR growth
1 year
▼ 2%
3 years · compounded
▲ 39%
5 years · compounded
▲ 40%

Revenue has grown at a compounded annual rate (CAGR) of 21% over five years, including 40% growth in the latest year. EBITDA fell 2% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.

Financial Statement Summary

MetricsFY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Profit and Loss Statement
Revenue from Operations
Other Income
Total Revenue₹881.76 Cr
Cost of Materials Consumed
Employee Benefit Expense
Finance Costs
Depreciation and Amortisation
Other Expenses
Total Expenses
EBITDA₹128.15 Cr
Profit Before Tax
Tax Expense
Net Profit (PAT)₹81.69 Cr
Balance Sheet
Share Capital
Reserves and Surplus
Net Worth (Total Equity)
Long-term Borrowings
Short-term Borrowings
Trade Payables
Total Liabilities
Fixed Assets
Investments
Inventories
Trade Receivables
Cash and Bank Balance
Total Assets

Financial Ratios

MetricsFY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Profitability
EBITDA Margin14.5%
Net Profit Margin9.3%
Return on Equity (ROE)
Return on Capital Employed (ROCE)
Return on Assets (ROA)
Liquidity and Debt
Current Ratio
Quick Ratio
Debt-to-Equity Ratio
Interest Coverage Ratio
Efficiency and Growth
Asset Turnover
Receivable Days
Payable Days
Inventory Days
Revenue Growth
Net Profit Growth

To see the full financial statements and ratios of Bristol-Myers Squibb India Private Limited, buy the company report.

Board of directors of Bristol-Myers Squibb India Private Limited

Bristol-Myers Squibb India has 4 current directors and 19 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Sanjay SharmaDirector24 May 20224 Years 5 MonthsCurrent
Raghavendra AgarwalDirector09 Oct 201412 Years 1 MonthsCurrent
Harsh Atul MehtaDirector06 May 20251 Years 6 MonthsCurrent
Anuradha GuptaDirector01 Apr 20251 Years 7 MonthsCurrent

Peer comparison

Bristol-Myers Squibb India Private Limited is compared with the 4 companies closest to it by revenue in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Merck Specialities Private Limited₹1,027.41 Cr (FY 2025)13.0%Mumbai, Maharashtra, India
Eli Lilly and Company (India ) Private Limited₹1,003.67 Cr (FY 2025)25.0%Haryana, India
Neelkanth Drugs Private Limited₹897.65 Cr (FY 2023)38.0%Hyderabad, Telangana, India
Bristol-Myers Squibb India Private Limitedthis company₹881.76 Cr (FY 2025)₹81.69 Cr9.3%40.0%Mumbai, Maharashtra, India
Meher Lifecare Private Limited₹789.83 Cr (FY 2025)10.0%Mumbai, Maharashtra, India

To see the full peer comparison of Bristol-Myers Squibb India Private Limited, buy the company report.

Auditor

Bristol-Myers Squibb India Private Limited is audited by Deloitte Haskins & Sells for the financial year 2025.

Auditor firmFinancial yearFirm registration number
Deloitte Haskins & SellsFY 2025117366W/W-100018

Shareholding

The shareholding of Bristol-Myers Squibb India Private Limited is on record for 5 financial years, the latest being FY 2025, split between promoters, domestic institutions, foreign institutions, public shareholders and others.

Shareholder categoryFY 2025FY 2024FY 2023FY 2022FY 2021
Promoters
Domestic institutional investors (DII)
Foreign institutional investors (FII)
Public
Others

To see the full shareholding pattern of Bristol-Myers Squibb India Private Limited, buy the company report.

Deals & funding

Bristol-Myers Squibb India Private Limited has 6 deals on record (5 funding rounds, 1 rights issue), with disclosed funding of ₹294.86 Cr; the latest was in October 2015.

Total deals
6
Funding rounds
5
Rights issue
1
Disclosed funding
₹294.86 Cr

Deals on record (5 of 6)

WhenDealAmountParties
Oct 2015Rights issue₹52 CrInvestors: Bristol-Mayers Squibb Pharmaceuticals International holdings Netherlands BV
Dec 2014Funding round₹48 CrInvestors: Bristol-Mayers Squibb Pharmaceuticals International holdings Netherlands BV
Mar 2013Funding round₹148.04 CrInvestors: Bristol-Mayers Squibb Pharmaceuticals International holdings Netherlands BV
Feb 2012Funding round₹52.05 CrInvestors: Bristol-Mayers Squibb Pharmaceuticals International holdings Netherlands BV
Oct 2009Funding round₹23.86 CrInvestors: Bristol-Mayers Squibb Pharmaceuticals International holdings Netherlands BV

To see the full deal history of Bristol-Myers Squibb India Private Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

Bristol-Myers Squibb India Private Limited has 8 MSME Form 1 returns on record between 2018 and 2024, listing 38 overdue payments to 12 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 12)

SupplierAmount dueDue sinceReported on
S K Logistics
an individual supplier
Zenith Leisure Holidays Limited
Artiligence Private Limited
S K Lotlikar and Co

To see the full MSME payment records of Bristol-Myers Squibb India Private Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

GST

Bristol-Myers Squibb India has 4 GST registrations: 3 active and 1 cancelled or inactive.

Total GSTINs
4
Active
3
Cancelled / inactive
1
GSTINStateStatusRegistered on
27AACCB4313Q1ZIMaharashtraActive01 Jul 2017
07AACCB4313Q1ZKDelhiActive01 Jul 2017
29AACCB4313Q1ZEKarnatakaActive01 Jul 2017

To see the full GST registrations and return filing status of Bristol-Myers Squibb India Private Limited, buy the company report.

Recent activity

Bristol-Myers Squibb India Private Limited has 23 board changes on record since 2008: 4 appointments and 19 cessations. The latest: Anuradha Gupta ceased to be Additional Director on 21 Sep 2025.

AGM
Bristol-Myers Squibb India Private Limited last Annual general meeting of members was held on 22 Sep 2025 as per latest MCA records.
Ceased
Anuradha Gupta ceased to be Additional Director.
Ceased
Harsh Atul Mehta ceased to be Additional Director.
Appointed
Harsh Atul Mehta was appointed as Director.
Appointed
Anuradha Gupta was appointed as Director.
Filing
Bristol-Myers Squibb India Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai.
Ceased
Srivatsan Krishnan ceased to be Additional Director.
Ceased
Sanjay Sharma ceased to be Additional Director.
Ceased
Prateek Tandon ceased to be Additional Director.
Appointed
Sanjay Sharma was appointed as Director.
Ceased
Ashwini Shrikant Deshpande ceased to be Director.
Ceased
Bhavik Himatlal Desai ceased to be Director.

14 earlier events are in the company report.

Frequently asked questions

Bristol-Myers Squibb India is an active foreign private limited company based in Mumbai, Maharashtra, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 30 June 2004 (22+ years old) and is registered under CIN U24230MH2004FTC147232.

Bristol-Myers Squibb India has 4 current directors:

The latest financial statements of Bristol-Myers Squibb India on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 22 September 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Bristol-Myers Squibb India is 27AACCB4313Q1ZI, registered in Maharashtra. The company has 4 GST registrations in all, of which 3 are active and 1 is cancelled or inactive. Other active GSTINs include 07AACCB4313Q1ZK (Delhi), 29AACCB4313Q1ZE (Karnataka).

The CIN (Corporate Identification Number) of Bristol-Myers Squibb India is U24230MH2004FTC147232. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Bristol-Myers Squibb India has 8 court cases on record: 2 filed by the company and 6 filed against it. 4 are pending. Most are in the high courts.

Bristol-Myers Squibb India was incorporated on 30 June 2004, making it 22+ years old. It is registered with the Registrar of Companies, Mumbai.

Bristol-Myers Squibb India has 6 deals on record (5 funding rounds, 1 rights issue), with disclosed funding of ₹294.86 Cr; the latest was in October 2015.

The peers of Bristol-Myers Squibb India by revenue are Merck Specialities Private Limited, Eli Lilly and Company (India ) Private Limited, Neelkanth Drugs Private Limited, Meher Lifecare Private Limited, all in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading).

Anuradha Gupta ceased to be Additional Director on 21 Sep 2025. Harsh Atul Mehta ceased to be Additional Director on 21 Sep 2025. Harsh Atul Mehta was appointed as Director on 06 May 2025. Bristol-Myers Squibb India has 23 board changes on record in total.

Bristol-Myers Squibb India has 8 MSME Form 1 returns on record between 2018 and 2024, listing 38 overdue payments to 12 micro and small suppliers. The latest return was filed on 29 Apr 2024.

Bristol-Myers Squibb India can be reached through the website bms.com. Its registered office is in Mumbai, Maharashtra, India.